Home Newsfeeds HC Wainwright & Co. Reiterates Buy on Immunocore Hldgs, Maintains $90 Price Target

HC Wainwright & Co. Reiterates Buy on Immunocore Hldgs, Maintains $90 Price Target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $90 price target.

byBenzinga Newsdesk

March 8, 2023

1 minute read

HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $90 price target.

Not Running Fast Enough: Hibbett Struggles With Lower Demand And Surging Inventory

By Shivani Kumaresan

May 26, 12:40 PM

Telsey Advisory Group analyst Cristina Fernández reiterated an Outperform rating on the shares of Hibbett Inc (NASDAQ:HIBB) with a price target of…

Analyst Ratings

Where Estee Lauder Cos Stands With Analysts

By Benzinga Insights

July 27, 8:01 AM

Over the past 3 months, 23 analysts have published their opinion on Estee Lauder Cos (NYSE:EL) stock. These…

Super Group Q1 Revenues Up On Higher Monthly Active Users, Forecasts Another Strong Quarter Ahead

By Nabaparna Bhattacharya

May 24, 11:49 AM

Super Group (SGHC) Limited (NYSE:SGHC) reported the first quarter of FY23 revenues of €338.5 million, up 1% year over year.…

SGHC

SVB Leerink Upgrades scPharmaceuticals to Outperform, Raises Price Target to $11

By Benzinga Newsdesk

October 11, 6:08 AM

SVB Leerink analyst Roanna Ruiz upgrades scPharmaceuticals (NASDAQ:SCPH) from Market Perform to Outperform and raises the price target from $6 to $11.

SCPH

HC Wainwright & Co. Reiterates Buy on Immunocore Hldgs, Maintains $90 Price Target

Related Posts

Not Running Fast Enough: Hibbett Struggles With Lower Demand And Surging Inventory

Where Estee Lauder Cos Stands With Analysts

Super Group Q1 Revenues Up On Higher Monthly Active Users, Forecasts Another Strong Quarter Ahead

SVB Leerink Upgrades scPharmaceuticals to Outperform, Raises Price Target to $11